Dicycloplatin

双环铂

Report date: 2026/03/12 20:00:16
NME

Base Information

Drug NameDicycloplatin
Drug Alias NameTP21TP-21
ClassificationSmall molecules
Mechanisms of ActionAlkylating agentsDNA inhibitors
TargetsDNA
Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantCarcinoma, Non-Small-Cell LungCarcinoma, Hepatocellular
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2012/05/28
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBeijing Suopingda Pharmaceutical Research Co LtdBeijing Xingda Science System Company
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBeijing Suopingda Pharmaceutical Research Co LtdBeijing Xingda Science System Company
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms, Castration-ResistantCarcinoma, Non-Small-Cell LungCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A